哌甲酯
延伸閱讀 > 參考資料

↑  Kimko, HC; Cross, JT; Abernethy, DR. . Clinical pharmacokinetics. December 1999, 37 (6): 457–70. PMID 10628897. doi:10.2165/00003088-199937060-00002.
1 2  . . National Center for Biotechnology Information. （原始内容存档于2014-01-06） 使用|archiveurl=需要含有|url= (帮助).  |section-url=被忽略 (帮助); |section=被忽略 (帮助); 使用|accessdate=需要含有|url= (帮助)
1 2 3  FDA. CONCERTA(methylphenidate HCl) Extended-release Tablets CIIPDF（167 KB） 2007
↑  . DailyMed. Novartis. 2017-01-05  [March, 2017.]. （原始内容存档于2017-03-20）. Methylphenidate hydrochloride USP is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77.  请检查|access-date=中的日期值 (帮助)
↑  www.ehow.com/about_5374709_ritalin-invented.html When Was Ritalin Invented?, citing Lawrence Diller: "Running on Ritalin", 1999
↑  
Diller, Lawrence. . 1999. ISBN 978-0553379068.
↑  
Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. . ADHD Attention Deficit and Hyperactivity Disorders. 2010, 2 (4): 241–55. PMC 3000907 . PMID 21258430. doi:10.1007/s12402-010-0045-8.
↑  . 2013-08-13  [2017-03-29]. （原始内容存档于2017-09-21） –www.bbc.com.
↑  .   [2017-03-29]. （原始内容存档于2017-09-21）.
↑  "Ritalin & Cocaine: The Connection and the Controversy" （页面存档备份，存于）. Learn.genetics.utah.edu. Retrieved on 2011-10-16.
↑  Mary Ann Boyd. . Lippincott Williams & Wilkins. 2005: 160–  [2011-04-30]. ISBN 978-0-7817-4916-9. （原始内容存档于2015-04-14）.
↑  Peter Doskoch. . NeuroPsychiatry Rev. 2002, 3 (1): 19  [2013-01-24]. （原始内容存档于2009-03-30）.
↑  . Medscape. 2006  [2013-10-08]. （原始内容存档于2017-09-08）. Catecholamines not only facilitate attention, they are essential to executive function. The prefrontal cortex directs behaviors, thoughts, and feelings represented in working memory. This representational knowledge is essential to fundamental cognitive abilities that compromise executive functions. These encompass the ability to (1) inhibit inappropriate behaviors and thoughts, (2) regulate our attention, (3) monitor our actions, and (4) plan and organize for the future. Difficulties with these prefrontal cortex functions are evident in neuropsychological and imaging studies of ADHD patients and account for many of the common behavioral symptoms. Measures of prefrontal cortical functioning in animals indicate that these functions are sensitive to small changes in catecholamine modulation of prefrontal cortex cells that can produce profound effects on the ability of the prefrontal cortex to guide behavior. Optimal levels of NE acting at postsynaptic alpha2A-adrenoceptors and dopamine acting at D1 receptors are essential to prefrontal cortex function. Blockade of norepinephrine alpha2-adrenoceptors in prefrontal cortex markedly impairs prefrontal cortex function and mimics most of the symptoms of ADHD, including impulsivity and locomotor hyperactivity. Conversely, stimulation of prefrontal cortical alpha2-adrenoceptors strengthens prefrontal cortex regulation of behavior and reduces distractibility. Thus, effective treatments for ADHD facilitate catecholamine transmission and apparently have their therapeutic actions by optimizing catecholamine actions in the prefrontal cortex
↑  
Arnsten AF, Li BM. . Biological Psychiatry. 2005, 57 (11): 1377–84. PMID 15950011. doi:10.1016/j.biopsych.2004.08.019.
↑  
Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ. . Pharmazie. Feb 2009, 64: 123–5. PMID 19322953.
↑  Fry JM. . Neurology. February 1998, 50 (2 Suppl 1): S43–S48. PMID 9484423. S2CID 36824088. doi:10.1212/WNL.50.2_Suppl_1.S43.
↑  Mitler MM. . Sleep. December 1994, 17 (8 Suppl): S103–S106. PMID 7701190. doi:10.1093/sleep/17.suppl_8.S103 .
↑  Markowitz, JS; Patrick, KS. . Journal of Clinical Psychopharmacology. June 2008, 28 (3 Suppl 2): S54–61. PMID 18480678. doi:10.1097/JCP.0b013e3181733560.
↑  Williard, RL; Middaugh, LD; Zhu, HJ; Patrick, KS. . Behavioural Pharmacology. February 2007, 18 (1): 39–51. PMID 17218796. doi:10.1097/fbp.0b013e3280143226.
1 2  Markowitz, JS; DeVane, CL; Pestreich, LK; Patrick, KS; Muniz, R. . Journal of child and adolescent psychopharmacology. December 2006, 16 (6): 687–98. PMID 17201613. doi:10.1089/cap.2006.16.687.
1 2  Heal DJ, Pierce DM. . CNS Drugs. 2006, 20 (9): 713–38. PMID 16953648. doi:10.2165/00023210-200620090-00002.
↑  Iversen L. . British Journal of Pharmacology. 2006, 147 (Suppl 1): S82–8. PMC 1760736 . PMID 16402124. doi:10.1038/sj.bjp.0706428.
↑  Sulzer D, Sonders MS, Poulsen NW, Galli A.  (PDF). Prog. Neurobiol. 2005, 75 (6): 406–33  [2013-01-21]. PMID 15955613. doi:10.1016/j.pneurobio.2005.04.003. （原始内容 (PDF)存档于2020-10-24）.
↑  Viggiano D, Vallone D, Sadile A. . Neural Plasticity. 2004, 11 (1–2): 102, 106–107. PMC 2565441 . PMID 15303308. doi:10.1155/NP.2004.97. Full-text  （页面存档备份，存于）
↑  Novartis: Focalin XR Overview （页面存档备份，存于）
↑  Focalin XR – Full Prescribing Information （页面存档备份，存于）. Novartis.
↑  SPC Concerta XL 18 mg – 36 mg prolonged release tablets （页面存档备份，存于） last updated on the eMC: 05/11/2010
↑  T. J. Volz. . Current Neuropharmacology. 2008  [2013-01-21]. PMC 2701286 . doi:10.2174/157015908787386041. （原始内容存档于2019-04-12）.
↑  Gordon N. . Int. J. Clin. Pract. 1999, 53 (7): 524–8. PMID 10692738.
↑  King S, Griffin S, Hodges Z;  et al. . Health Technol Assess. 2006, 10 (23): iii–iv, xiii–146  [2013-01-21]. PMID 16796929. （原始内容存档于2012-08-02）.  引文格式1维护：显式使用等标签 (link)
↑  Gonzalez de Dios J, Cardó E, Servera M. . Rev Neurol. 2006, 43 (12): 705–14. PMID 17160919 （西班牙语）.
↑  – Ritalin Side Effects （页面存档备份，存于）. Drugs.com. Retrieved on 2011-10-16.
↑  Jaanus SD. . Optom Clin. 1992, 2 (4): 73–96. PMID 1363080.
↑  Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL. . Sleep. 2005, 28 (6): 667–72. PMID 16477952.
↑   (PDF). Janssen Pharmaceuticals.   [2016-12-04]. （原始内容存档 (PDF)于2017-01-28）.
↑  Patrick KS, González MA, Straughn AB, Markowitz JS. . Expert Opinion on Drug Delivery. 2005, 2 (1): 121–43. PMID 16296740. doi:10.1517/17425247.2.1.121.
1 2  
Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS. . Drug metabolism and disposition: the biological fate of chemicals. 2000, 28 (6): 620–4. PMID 10820132.
↑  
Markowitz JS, Logan BK, Diamond F, Patrick KS. . Journal of Clinical Psychopharmacology. 1999, 19 (4): 362–6. PMID 10440465. doi:10.1097/00004714-199908000-00013.
↑  
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS. . Clinical pharmacology and therapeutics. March 2007, 81 (3): 346–53. PMC 3188424 . PMID 17339864. doi:10.1038/sj.clpt.6100082.
↑  
Roberts SM, DeMott RP, James RC. . Drug Metab. Rev. 1997, 29 (1–2): 329–53. PMID 9187524. doi:10.3109/03602539709037587.
↑  Chi-Yung Shang, Yi-Lei Pan, Hsiang-Yuan Lin, Lin-Wan Huang & Susan Shur-Fen Gau. . Journal of child and adolescent psychopharmacology. September 2015, 25 (7): 566–573. PMID 26222447. doi:10.1089/cap.2015.0035. At week 24, mean changes in ADHD-RS-IV Inattention scores were 13.58 points (Cohen's d, -3.08) for OROS-methylphenidate and 12.65 points (Cohen's d, -3.05) for atomoxetine; and mean changes in ADHD-RS-IV Hyperactivity-Impulsivity scores were 10.16 points (Cohen's d, -1.75) for OROS-methylphenidate and 10.68 points (Cohen's d, -1.87) for atomoxetine.
↑   (PDF). http://www.mohw.gov.tw/. 中華民國衛生福利部. June 2015  [February 2017]. （原始内容 (PDF)存档于2017-02-19）. 一般發現其對於專注度的改善沒有 MPH 明顯
↑  ,  (PDF), 中華民國衛生福利部/心理衛生專輯 1 1, 中華民國衛生福利部/心理衛生專輯/03注意力不足過動症.pdf: 中華民國衛生福利部: 22,  [June 2015]  [2020-10-04], ISBN 9789860454154, （原始内容 (PDF)存档于2017-02-19） （中文（繁體））, atomoxetine，用在病情 較為複雜、或是無法忍受MPH副作用的患者，然而一般發現其對於專注度的改善沒有MPH明顯
↑  . American Psychiatric Association (Guidelines (Tertiary source)). American Psychiatric Association & American Academy of Child and Adolescent Psychiatry (AACAP). July 2013  [January 2017]. （原始内容存档于2017-02-02）. Though not FDA-approved for combined treatment, atomoxetine (Strattera) is sometimes used in conjunction with stimulants as an off-label combination therapy.
↑  . MedlinePlus.gov. 2017-01-05  [January 2017]. （原始内容存档于2017-01-26）. Medicine combined with behavioral treatment often works best. Different ADHD medicines can be used alone or combined with each other. The doctor will decide which medicine is right, based on the person's symptoms and needs.
↑  Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M;  et al. . Journal of Child and Adolescent Psychopharmacology (systematic review (Secondary source)). 2013, 23 (3): 179–93. PMC 3696926 . PMID 23560600. doi:10.1089/cap.2012.0093. Existing evidence suggests, but does not confirm, that this drug combination may benefit some, but not all, patients who have tried several ADHD medications without success.
↑  Perugi G, Vannucchi G. . Expert Opin Pharmacother. 2015, 16 (14): 2193–204. PMID 26364896. doi:10.1517/14656566.2015.1079620. Although systematic trials on the use of stimulants and ATX in ADHD-BD comorbidity in adulthood are necessary, both treatments should be considered possible options to be carefully evaluated once the patient has been stabilized.
↑  . DailyMed.gov (Leaflet/label (Tertiary source)). Eli Lilly Company. June 2015  [February 2017]. （原始内容存档于2018-06-07）. 7.7 Methylphenidate\ Coadministration of methylphenidate with STRATTERA did not increase cardiovascular effects beyond those seen with methylphenidate alone.
↑  . DailyMed. Novartis. 2017-01-05  [March, 2017.]. （原始内容存档于2017-03-20）.  请检查|access-date=中的日期值 (帮助)
↑   (PDF). Novartis.com. Novartis. Mid 2015  [January, 2017.]. （原始内容存档 (PDF)于2017-08-30）.  请检查|access-date=, |date=中的日期值 (帮助)
1 2 3   (PDF). concerta.net. Jassen Cilag. 2013  [January, 2017.]. （原始内容 (PDF)存档于2017-01-17）.  请检查|access-date=中的日期值 (帮助)
1 2  Apotex Incorporation., , 鴻汶醫藥實業有限公司  (编),  (PDF), Canada, 2006-03-27  [2017-03-19], （原始内容存档 (PDF)于2009-11-22）
↑   (PDF), Canada: Apotex Incorporation., 2006-03-27  [2017-03-19], （原始内容存档 (PDF)于2009-11-22）
↑  . DailyMed.com. Novartis. Mid 2015  [January, 2017.]. （原始内容存档于2017-03-26）. Dosing Recommendations：Dosage should be individualized according to the needs and responses of the patients.）  请检查|access-date=, |date=中的日期值 (帮助)
↑  . DailyMed. Novartis. 2017-01-05  [March, 2017.]. （原始内容存档于2017-03-20）. Ritalin hydrochloride, methylphenidate hydrochloride USP, is a mild central nervous system (CNS) stimulant, available as tablets of 5, 10, and 20 mg for oral administration;  请检查|access-date=中的日期值 (帮助)
↑  . DailyMed.com. Novartis. 2017-01-05  [March, 2017.]. （原始内容存档于2017-03-20）. Dosage should be individualized according to the needs and responses of the patient.
Adults
Tablets: Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.

SR Tablets: Ritalin-SR tablets have a duration of action of approximately 8 hours. Therefore, Ritalin-SR tablets may be used in place of Ritalin tablets when the 8-hour dosage of Ritalin-SR corresponds to the titrated 8-hour dosage of Ritalin. Ritalin-SR tablets must be swallowed whole and never crushed or chewed.  参数|quote=值左起第85位存在換行符 (帮助); 请检查|access-date=中的日期值 (帮助)
↑  . DailyMed.com. Novartis. 2017-01-05  [March, 2017.]. （原始内容存档于2017-03-20）. Dosage should be individualized according to the needs and responses of the patient.
Children (6 years and over)
Ritalin should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.

If improvement is not observed after appropriate dosage adjustment over a 1-month period, the drug should be discontinued.

Tablets: Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.

SR Tablets: Ritalin-SR tablets have a duration of action of approximately 8 hours. Therefore, Ritalin-SR tablets may be used in place of Ritalin tablets when the 8-hour dosage of Ritalin-SR corresponds to the titrated 8-hour dosage of Ritalin. Ritalin-SR tablets must be swallowed whole and never crushed or chewed.  参数|quote=值左起第85位存在換行符 (帮助); 请检查|access-date=中的日期值 (帮助)
↑  . DailyMed.com. Novartis. Mid 2015  [January, 2017.]. （原始内容存档于2017-03-26）. Methylphenidate hydrochloride is a central nervous system (CNS) stimulant.
Ritalin LA® (methylphenidate hydrochloride) extended-release capsules is an extended-release formulation of methylphenidate with a bi-modal release profile. Ritalin LA uses the proprietary SODAS® (Spheroidal Oral Drug Absorption System) technology. Each bead-filled Ritalin LA capsule contains half the dose as immediate-release beads and half as enteric-coated, delayed-release beads, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. Ritalin LA 10, 20, 30, 40, and 60 mg capsules provide in a single dose the same amount of methylphenidate as dosages of 5, 10, 15, 20, or 30 mg of Ritalin tablets given b.i.d.）  参数|quote=值左起第75位存在換行符 (帮助); 请检查|access-date=, |date=中的日期值 (帮助)
↑  . DailyMed.com. Novartis. Mid 2015  [January, 2017.]. （原始内容存档于2017-03-26）. Initial Treatment
The recommended starting dose of Ritalin LA is 20 mg once daily. Dosage may be adjusted in weekly 10 mg increments to a maximum of 60 mg/day taken once daily in the morning, depending on tolerability and degree of efficacy observed. Daily dosage above 60 mg is not recommended. When in the judgement of the clinician a lower initial dose is appropriate, patients may begin treatment with Ritalin LA 10 mg.）  参数|quote=值左起第18位存在換行符 (帮助); 请检查|access-date=, |date=中的日期值 (帮助)
↑  . DailyMed.com. Novartis. Mid 2015  [January, 2017.]. （原始内容存档于2017-03-26）. Initial Treatment
The recommended starting dose of Ritalin LA is 20 mg once daily. Dosage may be adjusted in weekly 10 mg increments to a maximum of 60 mg/day taken once daily in the morning, depending on tolerability and degree of efficacy observed. Daily dosage above 60 mg is not recommended. When in the judgement of the clinician a lower initial dose is appropriate, patients may begin treatment with Ritalin LA 10 mg.）  参数|quote=值左起第18位存在換行符 (帮助); 请检查|access-date=, |date=中的日期值 (帮助)
↑  范洲际、李允武. 注意缺陷多动障碍的治疗药物进展PDF（242 KB）. 上海交通大学医学院附属第九人民医院. 2007.
↑  . RxList.   [2020-04-20]. （原始内容存档于2021-11-19） （英语）.
↑  . DailyMed.gov. Jassen Cilag. 2013  [January, 2017.]. （原始内容存档于2017-03-26）. 1 INDICATIONS AND USAGE \ 
CONCERTA® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see CLINICAL STUDIES (14)]. 

A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.  参数|quote=值左起第27位存在換行符 (帮助); 请检查|access-date=中的日期值 (帮助)
↑  . DailyMed.gov. Jassen Cilag. 2013  [January, 2017.]. （原始内容存档于2017-03-26）. 14.2 Adolescents
In a randomized, double-blind, multicenter, placebo-controlled trial (Study 4) involving 177 patients, CONCERTA® was demonstrated to be effective in the treatment of ADHD in adolescents aged 13 to 18 years at doses up to 72 mg/day (1.4 mg/kg/day). Of 220 patients who entered an open 4-week titration phase, 177 were titrated to an individualized dose (maximum of 72 mg/day) based on meeting specific improvement criteria on the ADHD Rating Scale and the Global Assessment of Effectiveness with acceptable tolerability. Patients who met these criteria were then randomized to receive either their individualized dose of CONCERTA® (18 – 72 mg/day, n=87) or placebo (n=90) during a two-week double-blind phase. At the end of this phase, mean scores for the investigator rating on the ADHD Rating Scale demonstrated that CONCERTA® was statistically significantly superior to placebo.  参数|quote=值左起第17位存在換行符 (帮助); 请检查|access-date=中的日期值 (帮助)
↑  . DailyMed.gov. Jassen Cilag. 2013  [January, 2017.]. （原始内容存档于2017-03-26）. 14.2 Adolescents
14.3 Adults
Two double-blind, placebo-controlled studies were conducted in 627 adults aged 18 to 65 years. The controlled studies compared CONCERTA® administered once daily and placebo in a multicenter, parallel-group, 7-week dose-titration study (Study 5) (36 to 108 mg/day) and in a multicenter, parallel-group, 5-week, fixed-dose study (Study 6) (18, 36, and 72 mg/day).

Study 5 demonstrated the effectiveness of CONCERTA® in the treatment of ADHD in adults aged 18 to 65 years at doses from 36 mg/day to 108 mg/day based on the change from baseline to final study visit on the Adult ADHD Investigator Rating Scale (AISRS). Of 226 patients who entered the 7-week trial, 110 were randomized to CONCERTA® and 116 were randomized to placebo. Treatment was initiated at 36 mg/day and patients continued with incremental increases of 18 mg/day (36 to 108 mg/day) based on meeting specific improvement criteria with acceptable tolerability. At the final study visit, mean change scores (LS Mean, SEM) for the investigator rating on the AISRS demonstrated that CONCERTA® was statistically significantly superior to placebo.

Study 6 was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study (5-week duration) with 3 fixed-dose groups (18, 36, and 72 mg). Patients were randomized to receive CONCERTA® administered at doses of 18 mg (n=101), 36 mg (n=102), 72 mg/day (n=102), or placebo (n=96). All three doses of CONCERTA® were statistically significantly more effective than placebo in improving CAARS (Conners' Adult ADHD Rating Scale) total scores at double-blind end point in adult subjects with ADHD.  参数|quote=值左起第17位存在換行符 (帮助); 请检查|access-date=中的日期值 (帮助)
↑  . DailyMed.com. Novartis. 2015  [January 2017]. （原始内容存档于2017-03-26）. Maintenance/Extended Treatment\There is no body of evidence available from controlled trials to indicate how long the patient with ADHD should be treated with Ritalin LA. It is generally agreed, however, that pharmacological treatment of ADHD may be needed for extended periods. Nevertheless, the physician who elects to use Ritalin LA for extended periods in patients with ADHD should periodically re-evaluate the long-term usefulness of the drug for the individual patient with trials off medication to assess the patient’s functioning without pharmacotherapy. Improvement may be sustained when the drug is either temporarily or permanently discontinued.）
↑  .   [2017-01-02]. （原始内容存档于2016-05-13）.
↑  国家食品药品监督管理局. . 医药网. 2007-10-31  [2013-02-04]. （原始内容存档于2020-07-02）.
↑  . www.hnysfww.com.   [2021-07-08]. （原始内容存档于2021-08-03）.
↑  . 永丰县卫生局办公室. 2012-02-09. （原始内容存档于2021-10-24）.
|  论 编春药 (西藥) |
| --- | --- |
肾上腺素:  Rauwolscine（英语：） (萝芙木属)  育亨宾 (Yohimbe（英语：）) 
雄激素:  DHT  睾酮  Tibolone（英语：） 
多巴胺:  ABT-670  ABT-724  苯丙胺  Apomorphine（英语：）  溴隱亭  丁氨苯丙酮  Cabergoline（英语：）  可卡因  氟班色林  L-多巴  Lisuride（英语：）  MDPV  甲氧麻黄酮  甲基苯丙胺  哌甲酯  Pergolide（英语：）  PF-219,061（英语：）  苯乙胺  Piribedil（英语：）  Pramipexole（英语：）  Quinagolide（英语：）  罗匹尼罗  Rotigotine（英语：）  Terguride（英语：） 
黑素皮质素:  黑色素细胞刺激素  Bremelanotide（英语：）  Melanotan II（英语：） 
PDE5抑製劑:  Acetildenafil（英语：）  Aildenafil（英语：）  Avanafil（英语：）  Icariin（英语：）  Lodenafil（英语：）  Mirodenafil（英语：）  MY-5445（英语：）  Nitrosoprodenafil（英语：）  西地那非（万艾可/威而鋼）  Sulfoaildenafil（英语：）  T-0156  他达拉非  Udenafil（英语：）  伐地那非 
其它相關:  亚硝酸酯 ("Rush Poppers")  GHB  催产素  THC（大麻）  UK-414,495（英语：）  抗利尿激素 
參見：娛樂性用藥
|  论 编致欣快劑 |
| --- | --- |
大麻素:  四氢大麻酚 
酒:  乙醇 
鴉片類藥物:  kratom（英语：）  Buprenorphine（英语：）  可待因  Dipipanone（英语：）  芬太尼  海洛因  Heterocodeine（英语：）  Hydromorphone（英语：）  美沙酮  嗎啡  鸦片  羟考酮  Oxymorphone（英语：）  哌替啶 
兴奋剂:  多巴胺能（英语：）興奮劑 苯丙胺  MDMA  甲基苯丙胺  可卡因  哌乙酯（英语：）  哌甲酯  膽鹼能（英语：）興奮劑 尼古丁 
吸入劑（英语：）:  一氧化二氮 
|  论 编σ受體調節劑 |
| --- | --- |
激動劑:  3-MeO-PCE（英语：）  3-MeO-PCP  3-PPP  4-MeO-PCP（英语：）  4-IBP  4-PPBP（英语：）  Afobazole（英语：）  Alazocine（英语：）  金刚烷胺  阿米替林  Arketamine（英语：）  BD-1008（英语：）  BD1031（英语：）  BD1052（英语：）  小檗鹼  Buprenorphine（英语：）  卡普托胺  西酞普兰  Clorgiline（英语：）  可卡因  Cutamesine  Cyclazocine（英语：）  DHEA  DHEA-S（英语：）  Desipramine（英语：）  Dextrallorphan（英语：）  右美沙芬  右啡烷  二甲啡烷  DMT  Donepezil（英语：）  DTG（英语：）  艾司西酞普兰  氟西汀  氟伏沙明  海洛因  Ibogaine（英语：）  Igmesine（英语：）  Imipramine（英语：）  JO-1784  氯胺酮  L-687,384（英语：）  拉莫三嗪  Lu 28-179  MDMA  美金刚胺  Metaphit（英语：）  甲基苯丙胺  Methoxetamine（英语：）  哌甲酯  嗎啡  Naluzotan（英语：）  Noscapine（英语：）  OPC-14523  Opipramol（英语：）  PB-28（英语：）  PD-144,415  喷他佐辛  Pentoxyverine（英语：）  苯环己哌啶  PRE-084  孕烯醇酮  Pregnenolone sulfate（英语：）  喹硫平  RTI-55（英语：）  SA-4503（英语：）  Siramesine（英语：）  Tapentadol（英语：）  Tenocyclidine（英语：）  曲马多  UMB23  UMB82  文拉法辛 
拮抗劑:  AC927（英语：）  AHD1  AZ66  BD1008（英语：）  BD1047（英语：）  BD1060（英语：）  BD1063（英语：）  BD1067（英语：）  BMY-14802（英语：）  CM156（英语：）  E-5842  氟哌啶醇  拉莫三嗪  LR132（英语：）  LR172  MIN-101（英语：）  MS-377  納洛酮  那曲酮  NE-100（英语：）  Panamesine  PD-144418  孕酮  奎孕酮  Rimcazole（英语：）  S1RA (E-52862)（英语：）  舍曲林  SM-21  SR-31742A  UMB100  UMB101  UMB103  UMB116  YZ-011  YZ-069  YZ-185 
未知物/ 未分類物:  4C-T-2（英语：）  5-MeO-DiPT  18-MC（英语：）  β-Endopsychosin  氯丙嗪  Clemastine（英语：）  Clocapramine（英语：）  Cloperastine（英语：）  D-Deprenyl（英语：）  DiPT  DPT  Gevotroline（英语：）  Nepinalone（英语：）  司来吉兰  TMA（英语：）; 變構調節劑: SKF-83959（英语：） 
| --- | --- |
：各地 :  德国  以色列  美国